IL13RA2 and Guillain-Barre syndrome: Clinical trials of IL13Rα2-CAR T-cell therapy in GB patients were basically initiated by local delivery of first-generation anti-IL13Rα2 CAR T-cells into the resection cavity of GBs and were improved with a second-generation, 4-1-BB co-stimulated construct, demonstrating promises for GB treatment and fair tolerance (NCT00730613) (53).